HN Gene F277L Mutation Enhances NDV Replication in Cancer Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic Newcastle Disease Virus (NDV) strains used in cancer therapy have limitations in therapeutic effectiveness, with a need for enhanced replication capabilities in human cancer cells while maintaining safety and efficacy profiles.
Innovation Solution
A modified NDV strain, NDV-MutHu, with specific mutations in the HN gene, particularly a change from phenylalanine to leucine at position 277, is developed to increase replication capability in human cancer cells, allowing for up to 10-fold higher replication compared to parent strains like MTH-68/H, and a reverse genetics system is used to generate recombinant NDV strains expressing therapeutic proteins such as Apoptin, B18R, and Nivolumab to enhance oncolytic and immune-stimulating properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current oncolytic NDV strains are used in cancer therapy, then safety toward normal cells is maintained, but therapeutic effectiveness and replication capability in human cancer cells is limited
Solution Approach 1:
The patent applies parameter changes by introducing specific mutations in the HN gene (particularly at position 277 where phenylalanine is replaced by leucine) to alter the viral replication characteristics. This genetic modification enables the virus to replicate more efficiently in human cancer cells while preserving its selective oncolytic activity and safety profile toward normal cells.
2Productivity
If NDV replication capability in human cancer cells is increased through mutation, then therapeutic effectiveness is enhanced, but risk of affecting safety toward normal cells may increase
Solution Approach 1:
The patent applies local quality by making specific localized mutations in the HN gene sequence rather than global modifications. The F277L mutation at a specific position in the HN protein confers enhanced replication capability in human cancer cells while the rest of the viral structure remains unchanged, preserving the tumor-selective replication property that ensures safety toward normal cells.
Solution Approach 2:
The patent employs feedback mechanisms where the mutated NDV strain is evaluated for both replication capability in cancer cells and safety toward normal cells. The F277L mutation demonstrates improved oncolytic activity while maintaining the virus's inherent tumor-selectivity, providing feedback that the modification is therapeutically beneficial without compromising safety.
3Reliability
If parent NDV strain MTH-68/H is used, then established safety and efficacy profile is maintained, but replication capability and therapeutic outcome can be further improved
Solution Approach 1:
The patent applies parameter changes by introducing specific mutations in the HN gene (particularly at position 277 where phenylalanine is replaced by leucine) to alter the viral replication characteristics. This genetic modification enables the virus to replicate more efficiently in human cancer cells while preserving its selective oncolytic activity and safety profile toward normal cells.
Data Source
AI summary
The invention relates to Newcastle Disease Vims (NDV), an avian paramyxovirus, which has been demonstrated to possess significant oncolytic activity against mammalian cancers. The invention provides the elucidation of the mechanisms of NDV-mediated oncolysis as well as the development of novel oncolytic viruses through the use of genetic engineering. The invention also provides a nucleic acid encoding a reverse genetically engineered (rg-)NDV having a mutation in the HN gene, said mutation allowing replication of said rgNDV in a cancer cell to a higher level than replication of an otherwise identical rgNDV not having said mutation in the HN gene.